MANAGEMENT OF RHEUMATIC CHOREA

An observational study

Alexandra Prufer de Queiroz Campos Araújo1, Paula Assunção Brito Pádua2, Heber Souza Maia Filho2

ABSTRACT - Background: Rheumatic chorea (RC) has recently been linked to an antibody-mediated immune mechanism. Objective/Method: To verify if this knowledge reflected in management changes we conceived a descriptive study. Results: The medical charts of 20 children (13 females) aged 6 to 12 years (mean 8 years), diagnosed as RC from June 1996 to June 1999, were reviewed. All patients received some medical treatment. Haloperidol was the most prescribed medication (15 patients - 75 %). Sulpiride, diazepam and valproate were also used as symptomatic treatment. Imune-modulating therapy with prednisone was prescribed for seven children. The shortest course of chorea (16 days) occurred in a patient treated with prednisone. Conclusion: Prednisone has been prescribed for rheumatic chorea besides the traditional symptomatic approach. A great variety of antichoreic drugs are being employed.

KEY WORDS: chorea, rheumatic fever, therapy, prognosis.

Sydenham’s chorea, or rheumatic chorea (RC), one of the major diagnostic criteria for rheumatic disease, is the most common acquired chorea during childhood. Characterized as an involuntary, non-stereotyped, arrhythmic and purposeless movement, it may be associated with other neurological abnormalities as hypotonia and behavioral disorders. Chorea in this setting is often considered a benign self-limiting condition.

The entire pathogeneses is not known. A link between the group A beta-haemolytic streptococcus through an antibody-mediated immune response targeting the basal ganglia has been described. Therefore, treatment with immunomodulators seems justified.

To verify if the acquired knowledge on the pathogeneses reflected in management changes of recently diagnosed RC cases, we conducted a descriptive cross-sectional study in a pediatric teaching institution.

METHOD

The Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG) is a pediatric hospital affiliated with the Federal University of Rio de Janeiro (UFRJ). We were able to list all patients diagnosed as chorea or rheumatic disease from June 1996 through June 1999, with the help of a coding system list of every day’s out-patient clinic. We included patients confirmed as RC, up to 16 years of age, seen during their acute episode of chorea and followed at least for three subsequent visits in our hospital.

Received 3 August 2001, received in final form 22 October 2001. Accepted 29 October 2001.

Dra. Alexandra Prufer de Queiroz Campos Araújo - Rua Gildásio Amado 55/211 - 22620-330 Rio de Janeiro RJ – Brasil. FAX: 55 21 2493 0792. E-mail alexprufer@hotmail.com
Children with other causes of chorea (congenital, hereditary, drug-induced, metabolic, endocrinological, infectious, or other autoimmune conditions) were excluded. Information was gathered from medical charts, data collected in Epiinfo 6 software and summarized using descriptive statistics.

The Review Board of the Federal University of Rio de Janeiro has approved this study.

RESULTS

One hundred and eight new cases of rheumatic disease were diagnosed and 24 of these were new chorea cases. Four were not included in this study due to insufficient follow-up. The age range from chorea patients was 6 to 12 years (mean 8 years), with a predominance of the female gender (65%). The follow-up varied from 4 months to 6 years and 9 months, and most (60%) were seen in the Neurology Unit. The others were followed by either the Cardiology or Rheumatology Unit.

Most of the patients came to medical care in less than ten days (60%). In only three, it took more than one month to reach the final diagnosis. All patients received some medical treatment for the chorea and all were prescribed penicillin for prophylaxis of streptococcal infections. Table 1 shows the main clinical features, dividing the seven patients that received prednisone as one of the drugs during treatment, from those that received only symptomatic treatment. Half of the children used more than one drug for chorea. Table 2 shows the order of treatment choice in our hospital. It was mainly a symptomatic management of chorea from the start with a predominance of haloperidol over all other drugs. This drug was the first choice of treatment whenever the children were seen by the pediatric cardiologist or rheumatologist. The neurologists prescribed a greater diversity of drugs. Sedation as adverse reaction occurred in a third of those treated with symptomatic drugs.

One patient used prednisone as his first and only treatment, and had the shortest course of chorea. Six other children received prednisone as second or third choice (one after using diazepam, two after haloperidol, one after valproate and sulpiride, two after diazepam and valproate). A third of the children treated with prednisone (15% of the treated with symptomatics) had chorea duration of less than 3 months.

The overall mean time to resolution of chorea was of 6 months (16 days - 22 months). There was no clear correlation between a faster resolution of chorea and a quicker start of the drugs as a whole (1 to 60 days for those who became asymptomatic in less than 6 months).

DISCUSSION

Pathogeneses of RC is nowadays better understood, but few changes in management and outcome are seen. Haloperidol, as a symptomatic controlling agent, is still the drug of choice in our set-

---

**Table 1. Clinical features and treatment options in rheumatic chorea, IPPMG/UFRJ, 1996-1999.**

<table>
<thead>
<tr>
<th></th>
<th>Prednisone treatment (n = 7)</th>
<th>Symptomatic treatment (n = 13)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>6</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>Carditis</td>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Emotional lability</td>
<td>5</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>Severity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unable to walk</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Admitted to hospital ward</td>
<td>2</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Recurrence</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

**Table 2. Treatment in rheumatic chorea patients, drug choice and sequential order, IPPMG/UFRJ, 1996-1999.**

<table>
<thead>
<tr>
<th>Drug</th>
<th>First choice</th>
<th>2nd choice</th>
<th>3rd choice</th>
<th>4th choice</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol</td>
<td>12</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Valproate</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Prednisone</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Diazepam</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Sulpiride</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>11</td>
<td>4</td>
<td>2</td>
<td>-</td>
</tr>
</tbody>
</table>
ing. Only a few patients (35%) are given prednisone as a therapy directed to the immune-mediated disorder.

The general features of this series, as the age range and a small higher prevalence of the female patients, compares to previous ones. Pure chorea was found in 30% of our patients, and as pointed out before should always be considered as rheumatic unless supported by other findings (congenital, hereditary, drug-induced, metabolic, endocrinological, infectious, or other autoimmune conditions). The mean time to the resolution of chorea in our population (6 months) matches with the natural history of this disease. Only a few patients became unable to walk (15%). This figure compares with those previously found (0-27%). As a therapy directed to the immune-mediated disorder, steroids have been used before and after the diagnosis of chorea. Nevertheless, only a controlled clinical trial would be able to support the greater effectiveness of steroids over symptomatic treatment. Steroids have been shown to be effective in RC as a main treatment choice appears to result from the absence of controlled trials with those other agents. Nevertheless the possibility of adverse reactions should prompt the use of safer drugs. Although a greater variety of drugs are being used in the treatment of RC, haloperidol is still the most common prescribed drug by non-neurologists. The current guidelines of the Brazilian Society of Pediatrics for treatment of RC in Brazil, elaborated by rheumatologists, recommend haloperidol. This seems to be the main reason for the prescription of this drug by the pediatricians. The literature concerning newer treatment options might not have reached the broader spectrum of clinicians that take part in the care of patients with rheumatic disease.

REFERENCES